Skip to main content
Top
Published in: BMC Health Services Research 1/2019

Open Access 01-12-2019 | Breast Cancer | Research article

Factors associated with readmissions in women participating in screening programs and treated for breast cancer: a retrospective cohort study

Authors: Carme Miret, Laia Domingo, Javier Louro, Teresa Barata, Marisa Baré, Joana Ferrer, Maria Carmen Carmona-García, Xavier Castells, Maria Sala

Published in: BMC Health Services Research | Issue 1/2019

Login to get access

Abstract

Background

We aimed to identify the risk factors associated with early, late and long-term readmissions in women diagnosed with breast cancer participating in screening programs.

Methods

We performed a multicenter cohort study of 1055 women aged 50–69 years participating in Spanish screening programs, diagnosed with breast cancer between 2000 and 2009, and followed up to 2014. Readmission was defined as a hospital admission related to the disease and/or treatment complications, and was classified as early (< 30 days), late (30 days-1 year), or long-term readmission (> 1 year). We used logistic regression to estimate the adjusted odds ratios (aOR), and 95% confidence intervals (95% CI) to explore the factors associated with early, late and long-term readmissions, adjusting by women’s and tumor characteristics, detection mode, treatments received, and surgical and medical complications.

Results

Among the women included, early readmission occurred in 76 (7.2%), late readmission in 87 (8.2%), long-term readmission in 71 (6.7%), and no readmission in 821 (77.8%). Surgical complications were associated with an increased risk of early readmissions (aOR = 3.62; 95%CI: 1.27–10.29), and medical complications with late readmissions (aOR = 8.72; 95%CI: 2.83–26.86) and long-term readmissions (aOR = 4.79; 95%CI: 1.41–16.31).

Conclusion

Our results suggest that the presence of surgical or medical complications increases readmission risk, taking into account the detection mode and treatments received. Identifying early complications related to an increased risk of readmission could be useful to adapt the management of patients and reduce further readmissions.

Trial Registration

ClinicalTrials.govIdentifier: NCT03165006. Registration date: May 22, 2017 (Retrospectively registered).
Appendix
Available only for authorised users
Literature
1.
go back to reference Torre L, Bray F, Siegel RL, Ferlay J, Lortet-tieulent J, Jemal A. Global Cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.CrossRefPubMed Torre L, Bray F, Siegel RL, Ferlay J, Lortet-tieulent J, Jemal A. Global Cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.CrossRefPubMed
2.
go back to reference International Agency for Research on Cancer, World Health Organization. GLOBOCAN 2018: cancer today. Breast cancer incidence in women, Spain 2018. International Agency for Research on Cancer, World Health Organization. GLOBOCAN 2018: cancer today. Breast cancer incidence in women, Spain 2018.
3.
go back to reference Jørgensen KJ, Zahl P-H, Gøtzsche PC. Breast cancer mortality in organised mammography screening in Denmark: comparative study. BMJ. 2010;340(5_Part_1):c1241.PubMedPubMedCentralCrossRef Jørgensen KJ, Zahl P-H, Gøtzsche PC. Breast cancer mortality in organised mammography screening in Denmark: comparative study. BMJ. 2010;340(5_Part_1):c1241.PubMedPubMedCentralCrossRef
4.
go back to reference Paci E, EUROSCREENWorking Group. Summary of the evidence of breast cancer service screening outcomes in Europe and first estimate of the benefit and harm balance sheet. J Med Screen. 2012;19(SUPPL. 1):5–13.PubMedCrossRef Paci E, EUROSCREENWorking Group. Summary of the evidence of breast cancer service screening outcomes in Europe and first estimate of the benefit and harm balance sheet. J Med Screen. 2012;19(SUPPL. 1):5–13.PubMedCrossRef
5.
go back to reference Independent UK Panel on Breast Cancer Screening, Marmot MG, Altman DG, Cameron DA, Dewar JA, Thompson SG, et al. The benefits and harms of breast cancer screening: an independent review. Br J Cancer. 2013;108:2205–40.CrossRef Independent UK Panel on Breast Cancer Screening, Marmot MG, Altman DG, Cameron DA, Dewar JA, Thompson SG, et al. The benefits and harms of breast cancer screening: an independent review. Br J Cancer. 2013;108:2205–40.CrossRef
6.
go back to reference Puigpinós-Riera R, Castillo Gómez A, Romero Morales A, Aller M, Castells X, Sala M. Social and clinical determinants of the use of health services in women with breast cancer (cohort DAMA). Gac Sanit. 2019;33(5):434–41.PubMedCrossRef Puigpinós-Riera R, Castillo Gómez A, Romero Morales A, Aller M, Castells X, Sala M. Social and clinical determinants of the use of health services in women with breast cancer (cohort DAMA). Gac Sanit. 2019;33(5):434–41.PubMedCrossRef
7.
go back to reference Mook S, Van’t Veer LJ, Rutgers EJ, Ravdin PM, Van De Velde AO, Van Leeuwen FE, et al. Independent prognostic value of screen detection in invasive breast cancer. J Natl Cancer Inst. 2011;103(7):585–97.PubMedCrossRef Mook S, Van’t Veer LJ, Rutgers EJ, Ravdin PM, Van De Velde AO, Van Leeuwen FE, et al. Independent prognostic value of screen detection in invasive breast cancer. J Natl Cancer Inst. 2011;103(7):585–97.PubMedCrossRef
8.
go back to reference Choi KS, Yoon M, Song SH, Suh M, Park B, Jung KW, et al. Effect of mammography screening on stage at breast cancer diagnosis: results from the Korea National Cancer Screening Program. Sci Rep. 2018;8(1):1–8.CrossRef Choi KS, Yoon M, Song SH, Suh M, Park B, Jung KW, et al. Effect of mammography screening on stage at breast cancer diagnosis: results from the Korea National Cancer Screening Program. Sci Rep. 2018;8(1):1–8.CrossRef
9.
go back to reference Sankatsing VDV, van Ravesteyn NT, Heijnsdijk EAM, Looman CWN, van Luijt PA, Fracheboud J, et al. The effect of population-based mammography screening in Dutch municipalities on breast cancer mortality: 20 years of follow-up. Int J Cancer. 2017;141(4):671–7.PubMedCrossRef Sankatsing VDV, van Ravesteyn NT, Heijnsdijk EAM, Looman CWN, van Luijt PA, Fracheboud J, et al. The effect of population-based mammography screening in Dutch municipalities on breast cancer mortality: 20 years of follow-up. Int J Cancer. 2017;141(4):671–7.PubMedCrossRef
10.
go back to reference Morrell S, Taylor R, Roder D, Robson B, Gregory M, Craig K. Mammography service screening and breast cancer mortality in New Zealand: a National Cohort Study 1999-2011. Br J Cancer. 2017;116(6):828–39.PubMedPubMedCentralCrossRef Morrell S, Taylor R, Roder D, Robson B, Gregory M, Craig K. Mammography service screening and breast cancer mortality in New Zealand: a National Cohort Study 1999-2011. Br J Cancer. 2017;116(6):828–39.PubMedPubMedCentralCrossRef
11.
go back to reference Tóth D, Varga Z, Tóth J, Árkosy P, Sebő É. Short- and long-term (10-year) results of an organized, population-based breast Cancer screening program: comparative, observational study from Hungary. World J Surg. 2018;42(5):1396–402.PubMedCrossRef Tóth D, Varga Z, Tóth J, Árkosy P, Sebő É. Short- and long-term (10-year) results of an organized, population-based breast Cancer screening program: comparative, observational study from Hungary. World J Surg. 2018;42(5):1396–402.PubMedCrossRef
12.
go back to reference Hofvind S, Holen, Aas T, Roman M, Sebuødegård S, Akslen LA. Women treated with breast conserving surgery do better than those with mastectomy independent of detection mode, prognostic and predictive tumor characteristics. Eur J Surg Oncol. 2015;41(10):1417–22.PubMedCrossRef Hofvind S, Holen, Aas T, Roman M, Sebuødegård S, Akslen LA. Women treated with breast conserving surgery do better than those with mastectomy independent of detection mode, prognostic and predictive tumor characteristics. Eur J Surg Oncol. 2015;41(10):1417–22.PubMedCrossRef
13.
go back to reference Løberg M, Lousdal ML, Bretthauer M, Kalager M. Benefits and harms of mammography screening. Breast Cancer Res. 2015;17(63):1–12. Løberg M, Lousdal ML, Bretthauer M, Kalager M. Benefits and harms of mammography screening. Breast Cancer Res. 2015;17(63):1–12.
14.
go back to reference Lai JK, Martin MA, Meyricke R, O’Neill T, Roberts S. Factors associated with short-term hospital readmission rates for breast Cancer patients in Western Australia: an observational study. J Am Coll Surg. 2007;204(2):193–200.PubMedCrossRef Lai JK, Martin MA, Meyricke R, O’Neill T, Roberts S. Factors associated with short-term hospital readmission rates for breast Cancer patients in Western Australia: an observational study. J Am Coll Surg. 2007;204(2):193–200.PubMedCrossRef
15.
go back to reference Nelson JA, Fischer JP, Chung C, Wu LC, Serletti JM, Kovach SJ. Risk of Readmission following Immediate breast reconstruction: results from the 2011 American College of Surgeons National Surgical Quality Improvement Program data sets. Plast Reconstr Surg. 2014;134(2):193e–201e.PubMedCrossRef Nelson JA, Fischer JP, Chung C, Wu LC, Serletti JM, Kovach SJ. Risk of Readmission following Immediate breast reconstruction: results from the 2011 American College of Surgeons National Surgical Quality Improvement Program data sets. Plast Reconstr Surg. 2014;134(2):193e–201e.PubMedCrossRef
16.
go back to reference Gani F, Lucas DJ, Kim Y, Schneider EB, Pawlik TM. Understanding variation in 30-day surgical readmission in the era of accountable care. JAMA Surg. 2015;150(11):1042.PubMedCrossRef Gani F, Lucas DJ, Kim Y, Schneider EB, Pawlik TM. Understanding variation in 30-day surgical readmission in the era of accountable care. JAMA Surg. 2015;150(11):1042.PubMedCrossRef
17.
go back to reference Chow I, Hanwright PJ, Hansen NM, Leilabadi SN, Kim JYS. Predictors of 30-day readmission after mastectomy: a multi-institutional analysis of 21,271 patients. Breast Dis. 2015;35(4):221–31.PubMedCrossRef Chow I, Hanwright PJ, Hansen NM, Leilabadi SN, Kim JYS. Predictors of 30-day readmission after mastectomy: a multi-institutional analysis of 21,271 patients. Breast Dis. 2015;35(4):221–31.PubMedCrossRef
18.
go back to reference Sun SX, Leung AN, Dillon PW, Hollenbeak CS. Length of stay and readmissions in mastectomy patients. Breast J. 2015;21(5):526–32.PubMedCrossRef Sun SX, Leung AN, Dillon PW, Hollenbeak CS. Length of stay and readmissions in mastectomy patients. Breast J. 2015;21(5):526–32.PubMedCrossRef
19.
go back to reference Landercasper J, Bennie B, Bray MS, Vang CA, Linebarger JH. Does neoadjuvant chemotherapy affect morbidity, mortality, reoperations, or readmissions in patients undergoing lumpectomy or mastectomy for breast cancer? Gland Surg. 2017;6(1):14–26.PubMedPubMedCentralCrossRef Landercasper J, Bennie B, Bray MS, Vang CA, Linebarger JH. Does neoadjuvant chemotherapy affect morbidity, mortality, reoperations, or readmissions in patients undergoing lumpectomy or mastectomy for breast cancer? Gland Surg. 2017;6(1):14–26.PubMedPubMedCentralCrossRef
20.
go back to reference Gibson S, McConigley R. Unplanned oncology admissions within 14 days of non-surgical discharge: a retrospective study. Support Care Cancer. 2016;24(1):311–7.PubMedCrossRef Gibson S, McConigley R. Unplanned oncology admissions within 14 days of non-surgical discharge: a retrospective study. Support Care Cancer. 2016;24(1):311–7.PubMedCrossRef
21.
go back to reference International Agency for Research on Cancer. Cancer screening in The European Union (2017). Recommendation on cancer screening 2017. International Agency for Research on Cancer. Cancer screening in The European Union (2017). Recommendation on cancer screening 2017.
22.
go back to reference Perry N, Broeders M, de Wolf C, Tornberg S, Holland R, von Karsa L. European guidelines for quality assurance in breast cancer screening and diagnosis. Fourth edition--summary document. Ann Oncol. 2006;19(4):614–22.CrossRef Perry N, Broeders M, de Wolf C, Tornberg S, Holland R, von Karsa L. European guidelines for quality assurance in breast cancer screening and diagnosis. Fourth edition--summary document. Ann Oncol. 2006;19(4):614–22.CrossRef
23.
go back to reference Amendoeira I, Anttila A, Bellocq J, Bianchi S, Bielska-Lasota M, Boecker W, et al. European guidelines for quality assurance in breast cancer screening and diagnosis (2013). Health & Consum Protec. European Communities/EUREF, editor. Vol. 19, Health & Consum Protec. 2006. p. 1–432. Amendoeira I, Anttila A, Bellocq J, Bianchi S, Bielska-Lasota M, Boecker W, et al. European guidelines for quality assurance in breast cancer screening and diagnosis (2013). Health & Consum Protec. European Communities/EUREF, editor. Vol. 19, Health & Consum Protec. 2006. p. 1–432.
24.
go back to reference Ascunce N, Salas D, Zubizarreta R, Almazán R, Ibáñez J, Ederra M, et al. Cancer screening in Spain. Ann Oncol. 2010;21(SUPPL.3):43–51. Ascunce N, Salas D, Zubizarreta R, Almazán R, Ibáñez J, Ederra M, et al. Cancer screening in Spain. Ann Oncol. 2010;21(SUPPL.3):43–51.
25.
go back to reference Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.PubMedCrossRef Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.PubMedCrossRef
26.
go back to reference Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn H-J, et al. Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast Cancer 2011. Ann Oncol. 2011;22(8):1736–47.PubMedPubMedCentralCrossRef Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn H-J, et al. Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast Cancer 2011. Ann Oncol. 2011;22(8):1736–47.PubMedPubMedCentralCrossRef
27.
go back to reference Halfon P, Eggli Y, Prêtre-Rohrbach I, Meylan D, Marazzi A, Burnand B. Validation of the potentially avoidable hospital readmission rate as a routine indicator of the quality of hospital care. Med Care. 2006;44(11):972–81.PubMedCrossRef Halfon P, Eggli Y, Prêtre-Rohrbach I, Meylan D, Marazzi A, Burnand B. Validation of the potentially avoidable hospital readmission rate as a routine indicator of the quality of hospital care. Med Care. 2006;44(11):972–81.PubMedCrossRef
28.
go back to reference Hynes DM, Weaver F, Morrow M, Folk F, Winchester DJ, Mallard M, et al. Breast cancer surgery trends and outcomes: results from a National Department of veterans affairs study. J Am Coll Surg. 2004;198(5):707–16.PubMedCrossRef Hynes DM, Weaver F, Morrow M, Folk F, Winchester DJ, Mallard M, et al. Breast cancer surgery trends and outcomes: results from a National Department of veterans affairs study. J Am Coll Surg. 2004;198(5):707–16.PubMedCrossRef
29.
go back to reference Hassett MJ, O’Malley AJ, Pakes JR, Newhouse JP, Earle CC. Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst. 2006;98(16):1108–17.PubMedCrossRef Hassett MJ, O’Malley AJ, Pakes JR, Newhouse JP, Earle CC. Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst. 2006;98(16):1108–17.PubMedCrossRef
30.
go back to reference Pittman NM, Hopman WM, Mates M. Emergency room visits and hospital admission rates after curative chemotherapy for breast Cancer. J Oncol Pract. 2015;11(2):120–5.PubMedCrossRef Pittman NM, Hopman WM, Mates M. Emergency room visits and hospital admission rates after curative chemotherapy for breast Cancer. J Oncol Pract. 2015;11(2):120–5.PubMedCrossRef
32.
go back to reference Baré M, Torà N, Salas D, Sentís M, Ferrer J, Ibáñez J, et al. Mammographic and clinical characteristics of different phenotypes of screen-detected and interval breast cancers in a nationwide screening program. Breast Cancer Res Treat. 2015;154(2):403–15.PubMedCrossRef Baré M, Torà N, Salas D, Sentís M, Ferrer J, Ibáñez J, et al. Mammographic and clinical characteristics of different phenotypes of screen-detected and interval breast cancers in a nationwide screening program. Breast Cancer Res Treat. 2015;154(2):403–15.PubMedCrossRef
Metadata
Title
Factors associated with readmissions in women participating in screening programs and treated for breast cancer: a retrospective cohort study
Authors
Carme Miret
Laia Domingo
Javier Louro
Teresa Barata
Marisa Baré
Joana Ferrer
Maria Carmen Carmona-García
Xavier Castells
Maria Sala
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Health Services Research / Issue 1/2019
Electronic ISSN: 1472-6963
DOI
https://doi.org/10.1186/s12913-019-4789-3

Other articles of this Issue 1/2019

BMC Health Services Research 1/2019 Go to the issue